Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation

Cancer Cell

Volumn 10, Issue 3, 2006, Pages 191-202

  Di Agostino, Silvia ^a   Strano, Sabrina ^a   Emiliozzi, Velia ^a   Zerbini, Valentina ^a   Mottolese, Marcella ^a   Sacchi, Ada ^a   Blandino, Giovanni ^a   Piaggio, Giulia ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

CELLCYCLE; DNA

Indexed keywords

CARCINOGEN; CCAAT BINDING FACTOR; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; HISTONE; MUTANT PROTEIN; NUCLEAR FACTOR Y; PROTEIN; PROTEIN CDC 25 C; PROTEIN P300; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF YA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CARCINOGENESIS; CELL CYCLE REGULATION; DNA DAMAGE; DNA SYNTHESIS; DRUG ACETYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR UPREGULATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 33748211158     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.08.013     Document Type: Article

References (40)

1. Adachi N., Nomoto M., Kohno K., and Koyama H. Cell-cycle regulation of the DNA topoisomerase IIα promoter is mediated by proximal CCAAT boxes: Possible involvement of acetylation. Gene 245 (2000) 49-57
2. Beroud C., and Soussi T. p53 mutation: Software and database. Nucleic Acids Res. 26 (1998) 200-204
3. Blandino G., Levine A.J., and Oren M. Mutant p53 gain of function: Differential effects p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18 (1999) 477-485
4. Bolognese F., Wasner M., Dohna C.L., Gurtner A., Ronchi A., Muller H., Manni I., Mossner J., Piaggio G., Mantovani R., et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 18 (1999) 1845-1853
5. Brummelkamp T.R., Bernards R., and Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296 (2002) 550-553
6. Caretti G., Salsi V., Vecchi C., Imbriano C., and Mantovani R. Dynamic recruitment of NF-Y and histone acetyltransferases on cell-cycle promoters. J. Biol. Chem. 278 (2003) 30435-30440
7. Di Como C.J., Urist M.J., Babayan I., Drobnjak M., Hedvat C.V., Teruya-Feldstein J., Pohar K., Hoos A., and Cordon-Cardo C. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 8 (2002) 494-501
8. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., and Levine A.J. Gain of function mutations in p53. Nat. Genet. 4 (1993) 42-46
9. El-Hizawi S., Lagowski J.P., Kulesz-Martin M., and Albor A. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res. 62 (2002) 3264-3270
10. Elkon R., Linhart C., Sharan R., Shamir R., and Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res. 13 (2003) 773-780
11. Farina A., Manni I., Fontemaggi G., Tiainen M., Cenciarelli C., Bellorini M., Mantovani R., and Piaggio G. Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene 18 (1999) 2818-2827
12. Farmer G., Friedlander P., Colgan J., Manley J.L., and Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24 (1996) 4281-4288
13. Fontemaggi G., Kela I., Amariglio N., Rechavi G., Krishnamurthy J., Strano S., Sacchi A., Givol D., and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol. Chem. 277 (2002) 43359-43368
14. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21 (2001) 1874-1887
15. Gualberto A.S., Aldape K., Kozakiewicz K., and Tlsty T. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc. Natl. Acad. Sci. USA 95 (1998) 5166-5171
16. Gurtner A., Manni I., Fuschi P., Mantovani R., Guadagni F., Sacchi A., and Piaggio G. Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol. Biol. Cell 14 (2003) 2706-2715
17. Hainaut P., and Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv. Cancer Res. 77 (2000) 81-137
18. Harris S.L., and Levine A.J. The p53 pathway: Positive and negative feedback loops. Oncogene 24 (2005) 2899-2908
19. Hu Z., Jin S., and Scotto K.W. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J. Biol. Chem. 275 (2000) 2979-2985
20. Huet X., Rech J., Plet A., Vie A., and Blanchard J.M. CyclinA expression is under negative transcriptional control during the cell cycle. Mol. Cell. Biol. 16 (1996) 3789-3798
21. Imbriano C., Gurtner A., Cocchiarella F., Di Agostino S., Basile V., Gostissa M., Dobbelstein M., Del Sal G., Piaggio G., and Mantovani R. Direct p53 transcriptional repression: In vivo analysis of CCAAT-containing G2/M promoters. Mol. Cell. Biol. 25 (2005) 3737-3751
22. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 68 (2004) 1145-1155
23. Kohn E.A., Ruth N.D., Brown M.K., Livingstone M., and Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J. Biol. Chem. 277 (2002) 26553-26564
24. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
25. Li R., Sutphin P.D., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., and Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene 16 (1998) 3269-3277
26. Lu H., and Levine A.J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92 (1995) 51-54
27. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., Engeland K., Sacchi A., Soddu S., and Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, Cyclin B2 and cdc25 promoters upon induced G2 arrest. J. Biol. Chem. 276 (2001) 5570-5576
28. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res. 26 (1998) 1135-1143
29. Murphy K.L., Dennis A.P., and Rosen J.M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. FASEB J. 14 (2000) 2291-2302
30. Prives C., and Hall P.A. The p53 pathway. J. Pathol. 187 (1999) 112-126
31. Salsi S., Caretti G., Wasner M., Reinhard W., Haugwitz U., Engeland K., and Mantovani R. Interactions between p300 and multiple NF-Y trimers govern cyclin B2 promoter function. J. Biol. Chem. 278 (2003) 6642-6650
32. Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Berges J., Helin K., Jansen-Durr P., and Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. USA 92 (1995) 11264-11268
33. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res. 60 (2000) 6788-6793
34. St Clair S., Giono L., Varmeh-Ziaie S., Resnick-Silverman L., Liu W., Padi A., Dastidar A., DaCosta J., Mattia M., and Manfredi J. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: One involves direct binding to the cdc25C promoter. Mol. Cell 16 (2004) 725-736
35. Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., Levine A.J., Sacchi A., Cesareni G., Oren M., et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275 (2000) 29503-29512
36. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., et al. Physical interaction with tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277 (2002) 18817-18826
37. Thompson P.R., Wang D., Wang L., Fulco M., Pediconi N., Zhang D., An W., Ge Q., Roeder R.G., Wong J., et al. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 11 (2004) 308-315
38. Van Ginkel P.R., Hsiao K.M., Schjerven H., and Farnham P.J. E2F-mediated growth regulation requires transcription factor cooperation. J. Biol. Chem. 272 (1997) 18367-18374
39. Yun J., Chae H.D., Choy H.E., Chung J., Yoo H.S., Han M.H., and Shin D.Y. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem. 274 (1999) 29677-29682
40. Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V., and Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25 (2006) 359-369